A multicenter, open-label phase II trial of secondline apatinib plus irinotecan in patients with advanced gastric cancer

被引：0
|
作者：
Peng, Jianjun
Li, Yong
Xiao, Jianjun
Liu, Huaqiang
机构：
[1] Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou, Peoples R China
[2] Tradit Chinese Med Hosp Guangdong Prov, Guangzhou, Peoples R China
[3] Zhongshan City Peoples Hosp, Zhongshan, Peoples R China
[4] Cent Hosp Guangdong Prov Agr Reclamat, Zhanjiang, Guangdong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.287
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
287
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Olaparib plus /- atezolizumab in patients with BRCA-mutated (BRCAmt) locally advanced unresectable or metastatic (advanced) breast cancer: an open-label, multicenter, randomized phase II trial
    Fanucci, Kristina A.
    Pilat, Mary Jo
    Shyr, Derek
    Shyr, Yu
    Boerner, Scott A.
    Durecki, Diane
    Noonan, Anne
    Abramson, Vandana
    Santa-Maria, Cesar
    Han, Hyo
    Nanda, Rita
    Dees, Elizabeth Claire
    Park, Haeseong
    Buys, Saundra
    Peswani, Namrata
    Chew, Helen
    Assad, Hadeel
    Wulf, Gerburg
    Richardson, Angelique
    Trivedi, Meghna S.
    Brufsky, Adam
    Abbruzzese, James
    Afghahi, Anosheh
    Sharon, Elad
    Schalper, Kurt
    LoRusso, Patricia
    CANCER RESEARCH, 2023, 83 (08)
  • [22] Apatinib for patients with advanced or recurrent cervical cancer: study protocol for an open-label randomized controlled trial
    Zhou, Jian-Guo
    Zhou, Nan-Jing
    Zhang, Qiong
    Feng, Yao-yao
    Zhou, Hang
    TRIALS, 2018, 19
  • [23] Apatinib for patients with advanced or recurrent cervical cancer: study protocol for an open-label randomized controlled trial
    Jian-Guo Zhou
    Nan-Jing Zhou
    Qiong Zhang
    Yao-yao Feng
    Hang Zhou
    Trials, 19
  • [24] TORIPALIMAB PLUS CHEMORADIOTHERAPY IN PATIENTS WITH RECURRENT OR METASTATIC CERVICAL CANCER: A MULTICENTER, OPEN-LABEL, SINGLE-ARM, PHASE II TRIAL
    Xu, Xiaoting
    Huan, Jian
    Miao, Hui
    Wang, Hao
    Wang, Yue
    Zhu, Hongyu
    Jiang, Jun
    Zhou, Juying
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A384 - A384
  • [25] Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial
    Guo, Honghai
    Ding, Ping'an
    Sun, Chenyu
    Yang, Peigang
    Tian, Yuan
    Liu, Yang
    Lowe, Scott
    Bentley, Rachel
    Li, Yaru
    Zhang, Zhidong
    Wang, Dong
    Li, Yong
    Zhao, Qun
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [26] Combination of anlotinib and irinotecan in the second-line treatment of patients with advanced colorectal cancer: An open-label, multicenter phase I/II study.
    Zhang, Bo
    Wang, Xi
    Zhu, Lingjun
    Li, Qun
    Liu, Yun
    Qi, Ling
    Shu, Yongqian
    Huang, Jing
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase II Trial
    Chen, Jiaying
    Ji, Qinghai
    Bai, Chunmei
    Zheng, Xiangqian
    Zhang, Yuan
    Shi, Feng
    Li, Xiaojiang
    Tang, Pingzhang
    Xu, Zhengang
    Huang, Rui
    Huang, Tao
    Pan, Yueyin
    Fan, Songhua
    Zhou, Jinghong
    Su, Weiguo
    THYROID, 2020, 30 (09) : 1245 - 1253
  • [28] An open label, multicenter, noninterventional study of apatinib in advanced gastric cancer patients (AHEAD-G202)
    Wang, Xiang
    Zhang, Ruixing
    Du, Nan
    Yang, Mudan
    Zang, Aimin
    Liu, Likun
    Yu, Junyan
    Gao, Jinghua
    Zhang, Junping
    Fu, Zhanzhao
    Ren, Yuchuan
    Ma, Liwen
    Guo, Jun
    Li, Qingshan
    Li, Xiaomei
    Fan, Zaiwen
    Song, Xiang
    Liu, Zheng
    Zhang, Yan
    Li, Guozhong
    Yu, Zhonghe
    Diao, Jianfeng
    Jia, Junmei
    Liang, Feng
    Wang, Huaqing
    Sun, Junzhong
    Gao, Yunge
    Yang, Ping
    Bai, Chunmei
    Ren, Xiubao
    Zhong, Diansheng
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [29] Phase II open-label study of sunitinib in patients with advanced breast cancer
    Denise A. Yardley
    E. Claire Dees
    Stephen D. Myers
    Sherry Li
    Paul Healey
    Zhixiao Wang
    Marla J. Brickman
    Jolanda Paolini
    Kenneth A. Kern
    Dennis L. Citrin
    Breast Cancer Research and Treatment, 2012, 136 : 759 - 767
  • [30] Phase II open-label study of sunitinib in patients with advanced breast cancer
    Yardley, Denise A.
    Dees, E. Claire
    Myers, Stephen D.
    Li, Sherry
    Healey, Paul
    Wang, Zhixiao
    Brickman, Marla J.
    Paolini, Jolanda
    Kern, Kenneth A.
    Citrin, Dennis L.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 136 (03) : 759 - 767
12345